natgillin/translations-raw huggingface dataset:
The most common side effect with NovoRapid (seen in between 1 and 10 patients in 100) is hypoglycaemia (low blood glucose levels).
Najpogostejši neželeni učinek zdravila NovoRapid (opažen pri 1 do 10 bolnikih od 100) je hipoglikemija (nizka koncentracija glukoze v krvi).
NovoRapid is normally used in combination with an intermediate- or long-acting insulin given at least once a day.
Običajno se uporablja v kombinaciji s srednjedolgodelujočim ali dolgodelujočim insulinom in se daje vsaj enkrat na dan.
For more information about treatment with NovoRapid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom NovoRapid preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
NovoRapid insulin aspart
Povzetek EPAR za javnost insulin aspart
It contains the active substance insulin aspart, a rapid-acting insulin.
Vsebuje zdravilno učinkovino insulin aspart, ki je hitro delujoči insulin.
It is given by injection under the skin in the abdominal (belly) wall, the thigh, the upper arm, the shoulder or the buttock.
Injicira se v podkožje trebušne stene (trebuha), stegna, nadlakti, ramena ali zadnjice.
NovoRapid is a replacement insulin that is very similar to the insulin made by the body but is absorbed faster by the body.
Zdravilo NovoRapid je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja telo vendar ga za razliko od humanega insulina telo hitreje absorbira.
NovoRapid can also be used in a pump system for continuous insulin infusion under the skin or alternatively, it can be given into a vein but only by a doctor or a nurse.
Poleg tega se lahko uporablja v sistemih s črpalko za kontinuirano infundiranje insulina pod kožo ali pa se vbrizga v veno, vendar ga tako smeta dati samo zdravnik ali medicinska sestra.
The studies compared NovoRapid with human insulin by measuring the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
V študijah so primerjali zdravilo NovoRapid s humanim insulinom z merjenjem koncentracije snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi uravnana.
NovoRapid gave almost identical results to human insulin in two studies involving 1,954 patients with type 1 diabetes (when the pancreas cannot produce insulin) and in one study involving 182 patients with type 2 diabetes (when the body is unable to use insulin effectively).
Rezultati za zdravilo NovoRapid so bili skoraj popolnoma enaki kot za humani insulin v dveh študijah, v katerih so zdravilo proučevali pri 1 954 bolnikih s sladkorno boleznijo tipa 1 (pri kateri trebušna slinavka ne more tvoriti insulina) in pri 182 bolnikih s sladkorno boleznijo tipa 2 (pri kateri telo ne more učinkovito izrabiti insulina).
The replacement insulin works in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Nadomestni insulin deluje enako kot naravno proizvedeni insulin in omogoča, da lahko glukoza iz krvi preide v celice.
For practical information about using NovoRapid, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila NovoRapid naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
NovoRapid is a solution for injection available in vials, cartridges (PenFill and PumpCart) and pre-filled pens (FlexPen, FlexTouch and InnoLet) and can only be obtained with a prescription.
Zdravilo NovoRapid je raztopina za injiciranje, ki je na voljo v vialah, injekcijskih vložkih (PenFill in PumpCart) in napolnjenih injekcijskih peresnikih (FlexPen, FlexTouch in InnoLet).
For the full list of all side effects and restrictions with NovoRapid, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila NovoRapid, glejte navodilo za uporabo.
NovoRapid has also given comparable results when studied in children from one year of age.
Primerljive rezultate je pokazalo tudi pri proučevanju zdravila pri otrocih, starejših od enega leta.
How is NovoRapid used?
Kako se zdravilo NovoRapid uporablja?
How does NovoRapid work?
Kako zdravilo NovoRapid deluje?
The safety has been found to be the same as human insulin when compared in two studies involving 349 pregnancies in women with type 1 or gestational diabetes (diabetes caused by pregnancy).
V dveh študijah, v kateri je bilo vključenih 349 nosečnic s sladkorno boleznijo tipa 1 ali nosečnostno sladkorno boleznijo (sladkorno boleznijo, ki se pojavi zaradi nosečnosti) so dokazali, da je njegova varnost enaka kot pri humanem insulinu.
The application was submitted to Ireland as reference Member State and Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Portugal, Spain and the United Kingdom as concerned Member States.
Vloga je bila predložena Irski kot referenčni državi članici ter Belgiji, Danski, Franciji, Nemčiji, Grčiji, Italiji, Luksemburgu, Nizozemski, Portugalski, Španiji in Združenemu kraljestvu kot zadevnim državam članicam.
The final opinion was converted into a Decision by the European Commission on 17 September 2012.
Končno mnenje je bilo 17. septembra 2012 spremenjeno v odločbo Evropske komisije.
The Committee appointed Prof Christian Friis as rapporteur and Dr David Murphy as co-rapporteur.
Odbor je imenoval prof. Christiana Friisa za poročevalca in dr. Davida Murphyja za soporočevalca.
Article 33(4) of Directive 2001/82/EC
Člen 33(4) Direktive 2001/82/ES.
The decentralised procedure (IE/V/0269/001/DC) started on 13 August 2010.
Decentralizirani postopek (IE/V/0269/001/DC) se je začel 13. avgusta 2010.
This application was an extension (Article 19 of Regulation 1234/2008/EC) to add sheep as new target species.
Pri tej vlogi je šlo za razširitev (člen 19 Uredbe 1234/2008/ES), s katero bi se ovce dodale kot nova ciljna vrsta.
During the procedure the applicant provided additional data and the issues raised by France regarding the proposed indications were resolved.
Med tem postopkom je predlagatelj predložil dodatne podatke in pomisleki, ki jih je izpostavila Francija o predlaganih indikacijah, so bili odpravljeni.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amendments to the Summary of Product Characteristics and package leaflet in the Annex III.
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s spremembami povzetka glavnih značilnosti zdravila in navodila za uporabo v Prilogi III.
Written explanations were provided by the applicant on 9 January 2012 and 23 April 2012.
Predlagatelj je 9. januarja in 23. aprila 2012 predložil pisna pojasnila ter 15. maja 2012 še ustna pojasnila.
The active substance is included in veterinary medicinal products currently authorised in several Member States in the European Union for use in cattle and pigs for the treatment of respiratory diseases.
Zdravilno učinkovino vsebujejo zdravila za uporabo v veterinarski medicini, ki so trenutno odobrena v več državah članicah Evropske unije za zdravljenje bolezni dihal pri govedu in prašičih.
Day 60 of the CMD(v) procedure was on 20 September 2011, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP.
Šestdeseti dan postopka CMD(v) je bil 20. september 2011, in ker zadevne države članice niso uspele doseči soglasja v zvezi z zdravilom, je bil postopek napoten na odbor CVMP.
Potential serious risks were identified during the decentralised procedure by two concerned Member States, by France regarding the proposed indications and by Denmark regarding the efficacy of the product.
Med decentraliziranim postopkom sta dve zadevni državi članici opredelili možna resna tveganja v zvezi s predlaganimi indikacijami (Francija) in učinkovitostjo zdravila (Danska).
On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 22 July 2011.
Ker ti pomisleki na 210. dan še vedno niso bili rešeni, je bila zadeva 22. julija 2011 v skladu s členom 33(1) Direktive 2001/82/ES napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v veterinarski medicini (CMD(v)).
Based on the rapporteurs' assessment of the currently available data, the CVMP considered that the benefit-risk profile of Nuflor 300 mg/ml solution for injection for cattle and sheep is positive subject to changes in the product information in order to clarify that the recommended treatment dose and treatment interval for sheep is based on the time mean florfenicol concentrations are maintained above MIC90.
Na podlagi ocene poročevalcev o trenutno razpoložljivih podatkih je odbor CVMP menil, da je razmerje med koristmi in tveganji za zdravilo Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce pozitivno pod pogojem, da se informacije o zdravilu dopolnijo s pojasnilom, da priporočeni terapevtski odmerek in interval odmerjanja temeljita na času, dokler se povprečne koncentracije florfenikola ohranjajo nad MIK90.
On 21 September 2011, the reference Member State, Ireland, notified to the European Medicines Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Dne 21. septembra 2011 je referenčna država članica, Irska, obvestila Evropsko agencijo za zdravila, da Usklajevalna skupina za postopek z medsebojnim priznavanjem in decentralizirani postopekzdravila za uporabo v veterinarski medicini (CMD(v)) ni dosegla soglasja glede zdravila, in zadevo napotila na odbor CVMP v skladu s členom 33(4) Direktive 2001/82/ES.
Therefore, the Committee adopted a positive opinion on 12 June 2012 recommending the granting of a marketing authorisation for Nuflor 300 mg/ml solution for injection for cattle and sheep.
Odbor je zato 12. junija 2012 sprejel pozitivno mnenje, v katerem priporoča odobritev dovoljenja za promet z zdravilom Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce.
Nuflor 300 mg/ml solution for injection for cattle and sheep contains 300 mg florfenicol per ml.
Zdravilo Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce vsebuje 300 mg florfenikola na mililiter.
Opinion following an Article 33(4) referral for Nuflor 300 mg/ml solution for injection for cattle and sheep
Mnenje v zvezi z napotitvijo v skladu s členom 33(4) za zdravilo Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce
The applicant, Intervet International BV, submitted an application for a decentralised procedure for Nuflor 300 mg/ml solution for injection for cattle and sheep.
Predlagatelj, družba Intervet International BV, je predložil vlogo za pridobitev dovoljenja za promet z zdravilom Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce po decentraliziranem postopku.
referral for Nuflor 300 mg/ml solution for injection for cattle and sheep
za zdravilo Nuflor 300 mg/ml raztopina za injiciranje za govedo in ovce
Date of first authorisation: 10 April 2014 Date of last renewal: 12 December 2018
Datum prve odobritve: 10. april 2014 Datum zadnjega podaljšanja: 12. december 2018
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU(seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
If you are an elderly patient (over 65 years of age), you should take Pregabalin Pfizer normally except if you have problems with your kidneys.
Če ste starejši bolnik (nad 65 let), lahko jemljete zdravilo Pregabalin Pfizer normalno, razen če imate težave z ledvicami.
Pregabalin Pfizer should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).
Zdravila Pregabalin Pfizer se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno (če koristi za mater jasno prevladajo nad možnim tveganjem za plod).
It is important to take your Pregabalin Pfizer capsules regularly at the same time each day.
Pomembno je, da kapsule Pregabalin Pfizer jemljete redno, vsak dan ob istem času.
Pregabalin Pfizer is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.
Zdravilo Pregabalin Pfizer ni namenjeno temu, da bi ga jemali samo, temveč ga je vedno treba uporabljati v kombinaciji z drugimi zdravili proti epilepsiji.
If you take more Pregabalin Pfizer than you should Call your doctor or go to the nearest hospital emergency unit immediately.
Če ste vzeli večji odmerek zdravila Pregabalin Pfizer, kot bi smeli Pokličite zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5-methylhexanoic acid].
Učinkovina pregabalin je analog gama-aminomaslene kisline [ (S)-3-(aminometil)-5-metilheksanojska kislina].
Pregabalin Pfizer and certain other medicines may influence each other (interaction).
Zdravilo Pregabalin Pfizer in določena druga zdravila imajo lahko medsebojno delovanje (interakcije).
If you have the impression that the effect of Pregabalin Pfizer is too strong or too weak, talk to your doctor or pharmacist.
Če imate občutek, da je učinek zdravila Pregabalin Pfizer premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Take your box or bottle of Pregabalin Pfizer capsules with you.
S seboj vzemite svojo škatlo ali plastenko kapsul Pregabalin Pfizer.
The safety and efficacy of Pregabalin Pfizer in children below the age of 12 years and in adolescents (12-17 years of age) have not been established.
Varnost in učinkovitost zdravila Pregabalin Pfizer pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Pfizer is taken together with medicines containing:
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Pfizer vzamemo skupaj z zdravili, ki vsebujejo:
These symptoms may occur more commonly or severely if you have been taking Pregabalin Pfizer for a longer period of time.
Ti znaki se lahko pojavljajo bolj pogosto in z večjo izrazitostjo, če ste zdravilo Pregabalin Pfizer jemali daljši čas.
Pregabalin Pfizer contains lactose monohydrate If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Zdravilo Pregabalin Pfizer vsebuje laktozo monohidrat Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte z zdravnikom.
Pregabalin Pfizer with food, drink and alcohol Pregabalin Pfizer capsules may be taken with or without food.
Zdravilo Pregabalin Pfizer skupaj s hrano, pijačo in alkoholom Kapsule Pregabalin Pfizer lahko jemljete s hrano ali brez nje.
4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
• Pregabalin Pfizer may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
• Uporaba zdravila Pregabalin Pfizer lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
For twice a day take Pregabalin Pfizer once in the morning and once in the evening, at about the same time each day.
Pregabalin Pfizer dvakrat na dan, ga vzemite enkrat zjutraj in enkrat zvečer, in sicer vsak dan ob približno istem času.
This increased risk was observed at low doses of pregabalin (≤ 300 mg, aOR 1.52 [95% CI, 1.04 - 2.22]) and there was a trend for a greater risk at high doses of pregabalin (> 300 mg, aOR 2.51 [95% CI 1.24 - 5.06]).
Povečano tveganje so opazili pri nizkih odmerkih pregabalina (≤ 300 mg, aOR 1,52 [95% IZ, 1,04 - 2,22]), opazili so tudi trend za povečano tveganje ob višjih odmerkih pregabalina (> 300 mg, aOR 2,51 [95% IZ, 1,24 - 5,06]).
What Pregabalin Pfizer is and what it is used for What you need to know before you take Pregabalin Pfizer How to take Pregabalin Pfizer Possible side effects
Kaj je zdravilo Pregabalin Pfizer in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Pregabalin Pfizer Kako jemati zdravilo Pregabalin Pfizer Možni neželeni učinki
Pregabalin Pfizer is available in seven pack sizes made of PVC with an aluminium foil backing: a 14 capsules pack containing 1 blister strip, a 21 capsules pack containing 1 blister strip, a 56 capsules pack containing 4 blister strips, a 84 capsules pack containing 4 blister strips, a 100 capsules pack containing 10 blister strips, a 112 capsules pack containing 8 blister strips and 100 x 1 capsules as perforated unit dose blisters.
Zdravilo Pregabalin Pfizer je na voljo v sedmih velikostih pakiranj iz PVC, dno je iz aluminijaste folije: pakiranje s 14 kapsulami v 1 pretisnem omotu, pakiranje z 21 kapsulami v 1 pretisnem omotu, pakiranje s 56 kapsulami v 4 pretisnih omotih, pakiranje s 84 kapsulami v 4 pretisnih omotih, pakiranje s 100 kapsulami v 10 pretisnih omotih, pakiranje s 112 kapsulami v 8 pretisnih omotih in 100 x 1 kapsula v perforiranem enoodmernem pretisnem omotu.
• Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability.
• občutek vznesenosti, zmedenost, dezorientiranost, zmanjšanje zanimanja za spolnost, razdražljivost
Pregabalin Pfizer may be taken with or without food.
Zdravilo Pregabalin Pfizer se lahko jemlje s hrano ali brez nje.
Continue taking Pregabalin Pfizer until your doctor tells you to stop.
Zdravilo Pregabalin Pfizer jemljite, dokler vam zdravnik ne naroči, da nehajte.
When taken with certain other medicines which have sedative effects (including opioids), Pregabalin Pfizer may potentiate these effects, and could lead to respiratory failure, coma and death.
Kadar ga vzamemo z določenimi drugimi zdravili, ki imajo sedativni učinek (vključno z opioidi), lahko zdravilo Pregabalin Pfizer stopnjuje te učinke, kar lahko vodi do zmanjšanega delovanja dihal, kome in smrti.
• Your doctor will tell you to take Pregabalin Pfizer either twice or three times a day.
• Zdravilo Pregabalin Pfizer morate vzeti dvakrat ali trikrat na dan.
If while taking Pregabalin Pfizer you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.
Če med jemanjem zdravila Pregabalin Pfizer zasledite zmanjšano izločanje urina, morate to povedati zdravniku, saj se lahko s prenehanjem jemanja zdravila stanje izboljša.
Epilepsy: Pregabalin Pfizer is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults.
Epilepsija: Zdravilo Pregabalin Pfizer se uporablja za zdravljenje določene oblike epilepsije (parcialnih napadov s sekundarno generalizacijo ali brez nje) pri odraslih.
• A small number of people being treated with anti-epileptics such as Pregabalin Pfizer have had thoughts of harming or killing themselves.
• Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Pfizer, so se pojavile misli na samopoškodovanje ali samomor.
Your doctor will prescribe Pregabalin Pfizer for you to help treat your epilepsy when your current treatment is not controlling your condition.
Zdravnik bo predpisal zdravilo Pregabalin Pfizer kot pomoč za zdravljenje epilepsije, če zdravila, ki jih trenutno uporabljate, bolezni ne obvladujejo.
Peripheral and central neuropathic pain: Pregabalin Pfizer is used to treat long lasting pain caused by damage to the nerves.
Periferna in centralna nevropatska bolečina: Zdravilo Pregabalin Pfizer se uporablja za zdravljenje dolgotrajne bolečine, nastale zaradi okvare živcev.
Pregabalin Pfizer should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor.
Zdravila Pregabalin Pfizer ne smete uporabljati med nosečnostjo ali dojenjem, razen če vam tako svetuje zdravnik.
Pregabalin Pfizer may have minor or moderate influence on the ability to drive and use machines.
Zdravilo Pregabalin Pfizer ima lahko blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
How to store Pregabalin Pfizer Contents of the pack and other information
Shranjevanje zdravila Pregabalin Pfizer Vsebina pakiranja in dodatne informacije
For three times a day take Pregabalin Pfizer once in the morning, once in the afternoon and once in the evening, at about the same time each day.
Če jemljete zdravilo Pregabalin Pfizer trikrat na dan, ga vzemite zjutraj, popoldne in zvečer, in sicer vsak dan ob približno istem času.
Pregabalin Pfizer may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.
Zdravilo Pregabalin Pfizer lahko povzroči omotico in somnolenco in tako lahko vpliva na sposobnost vožnje in upravljanja strojev.
If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Pregabalin Pfizer: • če ste alergični na pregabalin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
• There have been reports of heart failure in some patients when taking Pregabalin Pfizer; these patients were mostly elderly with cardiovascular conditions.
• Pri nekaterih bolnikih, ki so jemali zdravilo Pregabalin Pfizer, so opisani primeri srčnega popuščanja; večinoma je šlo za starejše bolnike s srčnožilnimi boleznimi.
• When Pregabalin Pfizer is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel).
• Ob sočasni uporabi zdravila Pregabalin Pfizer z ostalimi zdravili, ki lahko povzročijo zaprtost (kot so nekatera zdravila proti bolečinam), obstaja možnost pojava prebavnih težav (npr. zaprtje, zaprto ali paralizirano črevo).
Warnings and Precautions Talk to your doctor or pharmacist before taking Pregabalin Pfizer.
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Pregabalin Pfizer se posvetujte z zdravnikom ali farmacevtom.
Pregabalin Pfizer contains lactose monohydrate.
Zdravilo Pregabalin Pfizer vsebuje laktozo monohidrat.
Pregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.
Zdravilo Pregabalin Pfizer je indicirano za zdravljenje periferne in centralne nevropatske bolečine pri odraslih.
Pregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Zdravilo Pregabalin Pfizer je indicirano kot dodatno zdravljenje pri odraslih s parcialnimi napadi, s sekundarno generalizacijo ali brez nje.
You should take Pregabalin Pfizer in addition to your current treatment.
Zdravilo Pregabalin Pfizer morate jemati poleg trenutno uporabljanih zdravil.
• Some patients taking Pregabalin Pfizer have reported symptoms suggesting an allergic reaction.
• Nekateri bolniki, ki so jemali zdravilo Pregabalin Pfizer, so imeli simptome alergijske reakcije.
• Pregabalin Pfizer has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients.
• Zdravljenje z zdravilom Pregabalin Pfizer lahko spremljata omotica in zaspanost, ki lahko pri starejših bolnikih zvečata pogostnost nezgodnih poškodb (padcev).
Other medicines and Pregabalin Pfizer
Druga zdravila in zdravilo Pregabalin Pfizer